Summary Photofrin accumulation in malignant and host cell populations of various tumours was studied by flow cytometry analysis of cells dissociated from the tumour tissue. The transplantable mouse tumour models included in this analysis were sarcomas EMT6, RIF, KHT and FsaN, Lewis lung carcinoma, SCCVII squamous cell carcinoma (SCC) and slowly growing moderately differentiated AT17 SCC. An example of spontaneous mouse adenocarcinoma was also examined. Staining with specific monoclonal antibodies was used to identify the various cell populations present in these tumours. The main characteristic of Photofrin cellular accumulation was a very high photosensitiser content found exclusively in a subpopulation of tumourassociated macrophages (TAMs). Photosensitiser levels similar to or lower than in malignant cells were observed in the remaining TAMs and other tumour-infiltrating host cells. Photofrin accumulation in malignant cells was not equal in all tumour models, but may have been affected by tumour blood perfusion/ vascularisation. Results consistent with the above findings were obtained with SCC of buccal mucosa induced by 9,10-dimethyl-1,2-benzanthracene in Syrian hamsters. The TAM subpopulation that accumulates by far the highest cellular Photofrin levels in tumours is suggested to be responsible for the tumour-localised photosensitiser fluorescence.
Photofrin, clinically the most advanced photosensitiser for use in photodynamic therapy (PDT) of solid cancers, is an improved and purified preparation of haematoporphyrin derivative (HpD) (Dougherty, 1987) . The tumour-localised fluorescence of HpD and Photofrin administered systemically is a well established phenomenon , the nature of which is still not completely elucidated. Measurements of the concentration of Photofrin per gram of tumour tissue in animal models have shown that the levels in tumours compared with the surrounding normal tissues (e.g. muscle or skin) are similar or only slightly elevated (Bellnier and Henderson, 1992) . The difference in most cases cannot explain the strong in situ fluorescence of the drug which delineates the malignant lesion. This suggests that the photosensitiser accumulates preferentially in certain tumour elements, presumably localised in the lesion's surface. Whereas some photosensitisers (e.g. tetrasulphonated derivatives of tetraphenylporphine and aluminium phthalocyanine) localise more abundantly in acellular tumour structures (Peng et al., 1990) , Photofrin is known to accumulate in the cellular tumour compartment (Henderson and Fingar, 1989) . For the therapeutic potential of PDT it appears that the photosensitiser level in tumour cells is more important than the level retained in acellular tumour structures (Korbelik and Krosl, 1995a) . We have, therefore, concentrated on examining the Photofrin levels in different cellular populations contained in solid tumours. For this purpose, we have developed flow cytometry techniques for the determination of photosensitiser levels in cells dissociated from tumour tissue and are continuously working on their refinement.
In our first report, we showed (using the mouse SCCVII tumour model) that the population of cells characterised by the presence of the Fc receptor accumulates higher Photofrin levels than the malignant cell population, which is FcR negative (Korbelik et al., 1991) . The FcR-positive cell population in this tumour consists predominantly of tumour-associated macrophages (TAMs). Our subsequent goal was to identify and measure the photosensitiser content in all major cell populations that can be found in solid tumours. The results obtained with a model of mouse fibrosarcoma (FsaR) were recently reported (Korbelik and Krosl, 1995b) . They show that, with respect to Photofrin accumulation, a subpopulation of TAMs exceeds by far malignant cells and all other major host cell types present in this tumour. How representative this finding (with one type of transplantable tumour) is for different types of solid cancers remains to be established. We have suggested (Korbelik and Krosl, 1995a,b) that removing debris and substances that may be detrimental to the tumour, which will include entrapping the photosensitiser material, is a common physiological role of TAMs in various cancerous lesions. Hence, it is important to determine whether this factor (or some other elements) dominates the Photofrin accumulation in different types of tumours. Carcinomas and sarcomas should be examined at different degrees of differentiation, including the autochthonous tumours (carcinogen induced or spontaneous). In this report, we present the results on cellular Photofrin distribution obtained with a series of transplantable murine carcinomas and sarcomas, including a model of slowly growing moderately differentiated carcinoma and an example of the spontaneous murine adenocarcinoma. The data obtained with squamous cell carcinomas (SCCs) induced by 9,10-dimethyl-1,2-benzanthracene (DMBA) in the mucosa of hamster cheek pouch are also shown.
Materials and methods Tumour models
The transplantable tumours used in this study were implanted subcutaneously in syngeneic female mice 9-11 weeks of age. Growing in the C3H/HeN mice were KHT sarcoma (Kallman et al., 1967) , fibrosarcomas RIF (Twentyman et al., 1980) , FsaR and FsaN (Volpe et al., 1985) , and SCC models SCCVII (Suit et al., 1985) and AT17. Mice strains Balb/c and C57BL were used for the EMT6 mammary sarcoma (Rockwell et al., 1972) and Lewis lung carcinoma (LLC) (Sugiura and Stock, 1955) respectively. These tumours ranged from poorly immunogenic (e.g. SCCVII) to strongly immunogenic (e.g. EMT6). In vitro cultured cells were used for implantation of FsaR and FsaN tumours, as described previously (Korbelik and Krosl, 1995b) . The other tumours were implanted directly from maintenance tumours. The trocar method for implanting small (approximately 1 mm3) tumour fragments was required for the AT17 carcinomas, whereas the injection of 3-5 x 105 enzymatically dissociated cells was used with other tumour models. In contrast to the other tumours, which were rapidly growing and represented poorly differentiated sarcomas and carcinomas, the slowly growing AT17 carcinoma was moderately differentiated (as established by a histopathological examination). This tumour model was developed by Dr J Kummermehr (GSF, Neuherberg, Germany). An early serial passage (provided by Dr Al Minchinton) was used in this study.
A primary tumour that arose spontaneously on the left side of the lower abdominal area of a female C3H/HeN mouse (retired breeder) was also included in the study. Examination of histological sections and electron microscopy preparations from a fragment of the tumour taken after the excision revealed that this was a moderately differentiated adenocarcinoma.
All the tumours were used for experiments when they attained a size of 150-250 mg wet weight. The transplantable tumours reached the required size 12 days after implantation, except for the AT17 carcinomas, which were implanted 10 weeks earlier. The tumour-bearing mice were administered Photofrin (25 mg kg-') by intravenous injection. Photofring (porfimer sodium) was produced and provided by QLT Photo Therapeutics (Vancouver, BC, Canada).
The carcinogen DMBA (Sigma Chemical, St. Louis, MO, USA) was used for the induction of SCCs in the buccal pouch epithelium of outbred Syrian golden hamsters. Following the procedures described by Hemming et al. (1993) , the DMBA-impregnated silicone-coated sutures were inserted submucosally into the right cheeks of 7-week-old male hamsters. Two weeks after the implant, the site was painted with the DMBA solution (10 mg ml-1) in mineral oil, which was repeated weekly until a papillomatous lesion appeared. These lesions progressed to microinvasive cancers within 14-20 weeks after the suture implantation, and at this stage they were used for experiments. The hamsters were given Photofrin intraperitoneally using the same dose as with tumour-bearing mice (25 mg kg-').
Flow cytometry Tumour-bearing animals were sacrificed 24 h after receiving Photofrin. The excised tumours were minced with scalpels and then enzymatically dissociated into a single-cell suspension as described previously (Korbelik, 1993) . The viability of these cells ranged between 75% and 95%, showing some variation depending on the tumour model, but in most cases was over 90%. The cell yield varied between 4.5 x 107 and 2.5 x 108 cells per gram of tumour tissue depending on the tumour model.
In most experiments, the hearts were also excised from the mice immediately after the sacrifice. In the experiments with the hamster tumour model, hearts and normal mucosa tissue from the left cheek pouch were also used in the analysis. These tissues were minced and enzymatically digested using the same procedure as with tumour tissues. The erythrocytes present in suspensions of the heart muscle cells were removed by lysis, as described previously (Korbelik and Krosl, 1995b 
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. . Figure 5 for various types of murine carcinomas (top series) and sarcomas (lower series). Included in that analysis are average Photofrin levels in selected cells, gated on the basis of their extremely high photosensitiser content (as shown in Figure 3 ). In addition to TAMs, the leucocytes infiltrating the tumours examined in this study were found to consist of two major cell types, T lymphocytes (F4/80-cells stained positively for the common T cell antigen CD3) and other myeloid cells (F4/80-cells stained positively for the myeloid differentiation antigen GRI). Morphological examination suggests that a vast majority of GRI+F4/80-cells are monocytes or immature macrophages. The level of other immune cells that may be present (natural killer cells, B lymphocytes, mast cells) is much less than 1% of the total cell content, which precludes any significant role for these cells in the overall Photofrin tumour localisation. For each tumour model analysed in Figure 5 , a pie graph is inserted depicting the average per cent distribution of major cell populations. The pie graphs reemphasise in a more accurate way the impression from Figure 2 of the diversity of cellular composition of tumours. Whereas in AT17, KHT and RIF the leucocytes represent a minor fraction (30% or less), in EMT6 and especially FsaN tumour the TAM population is predominant. The GRI+F4/ 80-and CD3+F4/80-populations are minor in all tumours (1-5%, except in LLC which has on average 9% of T cells).
Despite considerable differences in cellular content, the The primary (non-transplanted) adenocarcinoma (shown in Figure 2 ) was also analysed in detail. The pattern of Photofrin distribution among the main cellular populations in this tumour was not different from that in transplantable mouse tumour models. Compared with the level in the malignant cells Photofrin content was 33 and 25 times higher in the selected and in the F4/80+CD25+ population respectively. This tumour contained 68% CD45-cells, 3% F4/80+CD25+ and 10% F4/80+CD25-cells. The selected cells represented 33% of all TAMs.
Besides immune cells non-immune host cells such as endothelial cells and normal fibroblasts are also found in solid tumours. In terms of total cellular content they (in tumour models examined in this study) represent a very minor fraction (<<1I%), which cannot have a significant role in the tumour localisation of photosensitisers. However, it was of interest to examine Photofrin levels in the endothelial cell population because vascular effects are known to be of a critical importance in the anti-tumour effect of PDT .
The endothelial cells in tumour cell suspensions were identified as CD31+CD45-, i.e. leucocytes that may stain positively to the CD31 antigen (PECAM-1 adhesion molecule) were excluded. A possible contamination with platelets (which are also CD31 positive) was eliminated by gating for cell-size objects. Still, the isolation of a pure endothelial cell fraction proves to be a challenging task. The CD31+CD45-population ranged only from 0.1% to 0.2% of the total cell population in tumours examined in this study, which makes it difficult to eliminate the risk of contamination with other cell types that could affect the measurement. The results of flow cytometry analysis represented by data obtained with AT17 and SCCVII tumours are shown in Figure 6 . Despite the concerns raised above, the fact that the results consistently showed no statistically significant difference in Photofrin level between CD31+CD45-and CD45-cell populations appears to be a reasonable indication that there is no substantial selectivity in photosensitiser accumulation in the endothelial cells of tumour vasculature. In addition to tumour tissue, hearts were also collected from the same mice. Photofrin content in the heart muscle cells dissociated by the enzymatic treatment was determined by the same flow cytometry technique. The results of the comparative analysis of photosensitiser levels in malignant cells (CD45-) of various tumours and heart muscle cells from the same animals are presented in Figure Cellular levels of Photofrin were also examined in DMBAinduced SCC growing in the cheek pouch of Syrian hamsters, which is one of the best characterised models for carcinogeninduced carcinoma (Salley, 1954) . Hamsters were administered Photofrin intraperitoneally, using the same dose as in tumour-bearing mice (25 mg kg-'), and were sacrificed 24 h later. Tumour tissue, normal mucosa tissue from the opposite cheek pouch and hearts were then taken for flow cytometry analysis. Since monoclonal antibodies to the hamster cell membrane antigens (equivalent to those employed in the mouse experiments) were not available to us, the FITCconjugated anti-hamster IgG was used to stain the tumour cell suspensions. This staining separates TAMs (which are FcR positive) from the malignant cell population (FcRcells), as shown previously in mouse tumour models (Korbelik et al., 1991) .
An example of Photofrin distribution among the cells of hamster SCC is shown in Figure 8a . In the same way as with mouse tumour models considerable heterogeneity in the photosensitiser cellular levels is evident. Another similarity to mouse tumours is the existence of a fraction of host immune cells characterised by elevated Photofrin content compared with the malignant cell fraction. The hamster SCC examined in this study contained, on average, three times more FcR-than FcR+ cells. The results of cellular Photofrin measurement (Figure 8b ) show over eight times higher photosensitiser levels in FcR+ cells than in FcR-cells. On the other hand, the average Photofrin level in the latter cell population was approximately two and 2.5 times higher than in the cells of buccal mucosa and the heart muscle respectively. Discussion A series of tumour models were used in this work for the investigation of Photofrin distribution among major cellular populations present in these lesions. The results confirmed our recently reported findings with a mouse fibrosarcoma model (Korbelik and Krosl, 1995b (Korbelik and Krosl, 1995b) .
The results of Photofrin measurement in endothelial cells (Figure 6 ) support the finding of in vitro studies that suggest that these cells do not exhibit preferential uptake of photosensitisers (Gomer et al., 1988) .
Comparative analysis of Photofrin accumulation in malignant cells of various tumours (Figure 7 ) reveals that the selectivity of localisation of the photosensitiser is not the same in all types of cancerous lesions. Different types of tumours growing in syngeneic inbred mice siblings can accumulate markedly different Photofrin levels not only in malignant cells, but the overall cellular levels can be higher or lower depending presumably on the blood perfusion/ vascularisation of the tumour as well.
The TAM subpopulation that excels above all other cell populations in tumours (and in surrounding normal tissues) in Photofrin accumulation can be the determinant of tumour localised photosensitiser fluorescence referred to in the introduction. This is supported by the evidence that in human malignancies, TAMs preferentially localise in the lesion's periphery (Bucana et al., 1992; Svennevig and Svaar, 1979) .
Further implications of the above described Photofrin distribution in malignant and host cell populations contained in tumours, e.g. the relevance with respect to the outcome of PDT, were elaborated on in our related papers (Korbelik and Krosl, 1995a,b) .
